Advertisement


Luis M. Montuenga, PhD, on Noninvasive Biomarkers in Lung Cancer Screening

IASLC 2020 World Conference on Lung Cancer in Singapore

Advertisement

Luis M. Montuenga, PhD, of the University of Navarra, discusses the potential contributions of biomarkers, promising biomarker panels being tested and published, the need to standardize biospecimen collection, and how to improve the sensitivity of these biomarkers (Abstract PL05.06).



Related Videos

Lung Cancer

Silvia Novello, MD, PhD, on NSCLC: Pharmacogenomics-Driven vs Standard Adjuvant Chemotherapy

Silvia Novello, MD, PhD, of the University of Turin, disc...

Lung Cancer

Roy S. Herbst, MD, PhD, on NSCLC: Osimertinib and Patient-Reported Outcomes

Roy S. Herbst, MD, PhD, of Yale University, discusses two key abstracts from the ADAURA trial: the use of osimertinib as adjuvant therapy for resected EGFR-mutated n...

Lung Cancer
Immunotherapy

Fred R. Hirsch, MD, PhD, on Lung Cancer: Survival and Tumor Mutation Burden

Fred R. Hirsch, MD, PhD, of Mount Sinai Medical Center, discusses Lung-MAP studies in which a higher tumor mutation burden determined by next-generation sequencing was linked...

Lung Cancer

Jill Feldman: A Determined Cancer Survivor Shares Her Story of a Family Devastated by Lung Cancer

Jill Feldman, a patient advocate who has lost five family members to lung cancer and is herself a 12-year cancer survivor living with EGFR-positive disease, describe...

Lung Cancer
Immunotherapy

Martin Reck, MD, PhD, on NSCLC: Pembrolizumab Plus Ipilimumab in First-Line Treatment

Martin Reck, MD, PhD, of the LungenClinic, discusses findings of the KEYNOTE-598 study, which showed that pembrolizumab plus ipilimumab was more toxic and offered no more ben...

Advertisement

Advertisement



Advertisement